BioSpace News Archive

PHC Corporation of North America, supplier of the PHCbi brand of cell preservation and growth products in the North America and Latin America markets, is pleased to announce that the PHCbi brand VIP ECO® SMART ultra-low temperature freezer has been awarded the prestigious Outstanding New Product Award for 2023 by the International Society for Biological and Environmental Repositories.

As the need for more advanced technology continues to grow, TGH Imaging is increasing patient access across four counties for breast cancer screening by adding Genius™ 3D Mammography™ exams made by Hologic to 18 locations in Hillsborough, Pasco, Pinellas and Palm Beach counties.

Waypoint Orthopedics, Inc., a spinal medical device company, announces that the company’s Waypoint GPS™ - a smart bone awl for use during pedicle screw pilot hole drilling - has received 510k clearance from the U.S. Food and Drug Administration.

Biologist and famed atheist Richard Dawkins has repeatedly described a test that he predicted would prove evolution, but now, mounting scientific evidence shows that the same test instead proves intelligent design, says Discovery Institute’s Center for Science & Culture.

VBL Therapeutics, announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, provided a corporate update and reported financial results for the first quarter ended March 31, 2023.

Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the quarter ended March 31, 2023.

NexImmune, Inc. (Nasdaq: NEXI) today reported financial results for the first quarter 2023.

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the first quarter ended March 31, 2023.

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.